1 Study Coverage 1.1 Overactive Bladder (OAB) Therapeutics Product Introduction 1.2 Market Segments 1.3 Key Overactive Bladder (OAB) Therapeutics Manufacturers Covered: Ranking by Revenue 1.4 Market by Type 1.4.1 Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Type 1.4.2 Anticholinergic Agents 1.4.3 Beta-3 Adrenoreceptor Agonists 1.5 Market by Application 1.5.1 Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Application 1.5.2 Hosptial 1.5.3 Clinci 1.5.4 Other 1.6 Study Objectives 1.7 Years Considered 2 Executive Summary 2.1 Global Overactive Bladder (OAB) Therapeutics Market Size, Estimates and Forecasts 2.1.1 Global Overactive Bladder (OAB) Therapeutics Revenue 2015-2026 2.1.2 Global Overactive Bladder (OAB) Therapeutics Sales 2015-2026 2.2 Global Overactive Bladder (OAB) Therapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026 2.3 Overactive Bladder (OAB) Therapeutics Historical Market Size by Region (2015-2020) 2.3.1 Global Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario in Sales by Region: 2015-2020 2.3.2 Global Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020 2.4 Overactive Bladder (OAB) Therapeutics Market Estimates and Projections by Region (2021-2026) 2.4.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Region (2021-2026) 2.4.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Region (2021-2026) 3 Global Overactive Bladder (OAB) Therapeutics Competitor Landscape by Players 3.1 Global Top Overactive Bladder (OAB) Therapeutics Sales by Manufacturers 3.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Manufacturers (2015-2020) 3.1.2 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2015-2020) 3.2 Global Overactive Bladder (OAB) Therapeutics Manufacturers by Revenue 3.2.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers (2015-2020) 3.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2015-2020) 3.2.3 Global Overactive Bladder (OAB) Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020) 3.2.4 Global Top 10 and Top 5 Companies by Overactive Bladder (OAB) Therapeutics Revenue in 2019 3.2.5 Global Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Global Overactive Bladder (OAB) Therapeutics Price by Manufacturers 3.4 Global Overactive Bladder (OAB) Therapeutics Manufacturing Base Distribution, Product Types 3.4.1 Overactive Bladder (OAB) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Overactive Bladder (OAB) Therapeutics Product Type 3.4.3 Date of International Manufacturers Enter into Overactive Bladder (OAB) Therapeutics Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026) 4.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Type (2015-2020) 4.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2015-2020) 4.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2015-2020) 4.1.3 Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) by Type (2015-2026) 4.2 Global Overactive Bladder (OAB) Therapeutics Market Size Forecast by Type (2021-2026) 4.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Type (2021-2026) 4.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Type (2021-2026) 4.2.3 Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026) 4.3 Global Overactive Bladder (OAB) Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Market Size by Application (2015-2026) 5.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Application (2015-2020) 5.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2015-2020) 5.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2015-2020) 5.1.3 Overactive Bladder (OAB) Therapeutics Price by Application (2015-2020) 5.2 Overactive Bladder (OAB) Therapeutics Market Size Forecast by Application (2021-2026) 5.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Application (2021-2026) 5.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Application (2021-2026) 5.2.3 Global Overactive Bladder (OAB) Therapeutics Price Forecast by Application (2021-2026) 6 Japan by Players, Type and Application 6.1 Japan Overactive Bladder (OAB) Therapeutics Market Size YoY Growth 2015-2026 6.1.1 Japan Overactive Bladder (OAB) Therapeutics Sales YoY Growth 2015-2026 6.1.2 Japan Overactive Bladder (OAB) Therapeutics Revenue YoY Growth 2015-2026 6.1.3 Japan Overactive Bladder (OAB) Therapeutics Market Share in Global Market 2015-2026 6.2 Japan Overactive Bladder (OAB) Therapeutics Market Size by Players (International and Local Players) 6.2.1 Japan Top Overactive Bladder (OAB) Therapeutics Players by Sales (2015-2020) 6.2.2 Japan Top Overactive Bladder (OAB) Therapeutics Players by Revenue (2015-2020) 6.3 Japan Overactive Bladder (OAB) Therapeutics Historic Market Review by Type (2015-2020) 6.3.1 Japan Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2015-2020) 6.3.2 Japan Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2015-2020) 6.3.3 Japan Overactive Bladder (OAB) Therapeutics Price by Type (2015-2020) 6.4 Japan Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts by Type (2021-2026) 6.4.1 Japan Overactive Bladder (OAB) Therapeutics Sales Forecast by Type (2021-2026) 6.4.2 Japan Overactive Bladder (OAB) Therapeutics Revenue Forecast by Type (2021-2026) 6.4.3 Japan Overactive Bladder (OAB) Therapeutics Price Forecast by Type (2021-2026) 6.5 Japan Overactive Bladder (OAB) Therapeutics Historic Market Review by Application (2015-2020) 6.5.1 Japan Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2015-2020) 6.5.2 Japan Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2015-2020) 6.5.3 Japan Overactive Bladder (OAB) Therapeutics Price by Application (2015-2020) 6.6 Japan Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts by Application (2021-2026) 6.6.1 Japan Overactive Bladder (OAB) Therapeutics Sales Forecast by Application (2021-2026) 6.6.2 Japan Overactive Bladder (OAB) Therapeutics Revenue Forecast by Application (2021-2026) 6.6.3 Japan Overactive Bladder (OAB) Therapeutics Price Forecast by Application (2021-2026) 7 North America 7.1 North America Overactive Bladder (OAB) Therapeutics Market Size YoY Growth 2015-2026 7.2 North America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country 7.2.1 North America Overactive Bladder (OAB) Therapeutics Sales by Country (2015-2020) 7.2.2 North America Overactive Bladder (OAB) Therapeutics Revenue by Country (2015-2020) 7.2.3 U.S. 7.2.4 Canada 8 Europe 8.1 Europe Overactive Bladder (OAB) Therapeutics Market Size YoY Growth 2015-2026 8.2 Europe Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country 8.2.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Country 8.2.2 Europe Overactive Bladder (OAB) Therapeutics Revenue by Country 8.2.3 Germany 8.2.4 France 8.2.5 U.K. 8.2.6 Italy 8.2.7 Russia 9 Asia Pacific 9.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Size YoY Growth 2015-2026 9.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country 9.2.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region (2015-2020) 9.2.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region 9.2.3 China 9.2.4 Japan 9.2.5 South Korea 9.2.6 India 9.2.7 Australia 9.2.8 Taiwan 9.2.9 Indonesia 9.2.10 Thailand 9.2.11 Malaysia 9.2.12 Philippines 9.2.13 Vietnam 10 Latin America 10.1 Latin America Overactive Bladder (OAB) Therapeutics Market Size YoY Growth 2015-2026 10.2 Latin America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country 10.2.1 Latin America Overactive Bladder (OAB) Therapeutics Sales by Country 10.2.2 Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country 10.2.3 Mexico 10.2.4 Brazil 10.2.5 Argentina 11 Middle East and Africa 11.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size YoY Growth 2015-2026 11.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country 11.2.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country 11.2.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country 11.2.3 Turkey 11.2.4 Saudi Arabia 11.2.5 U.A.E 12 Company Profiles 12.1 Allergan 12.1.1 Allergan Corporation Information 12.1.2 Allergan Description and Business Overview 12.1.3 Allergan Sales, Revenue and Gross Margin (2015-2020) 12.1.4 Allergan Overactive Bladder (OAB) Therapeutics Products Offered 12.1.5 Allergan Recent Development 12.2 Astellas Pharma 12.2.1 Astellas Pharma Corporation Information 12.2.2 Astellas Pharma Description and Business Overview 12.2.3 Astellas Pharma Sales, Revenue and Gross Margin (2015-2020) 12.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Products Offered 12.2.5 Astellas Pharma Recent Development 12.3 Hisamitsu Pharmaceutical 12.3.1 Hisamitsu Pharmaceutical Corporation Information 12.3.2 Hisamitsu Pharmaceutical Description and Business Overview 12.3.3 Hisamitsu Pharmaceutical Sales, Revenue and Gross Margin (2015-2020) 12.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered 12.3.5 Hisamitsu Pharmaceutical Recent Development 12.4 Pfizer 12.4.1 Pfizer Corporation Information 12.4.2 Pfizer Description and Business Overview 12.4.3 Pfizer Sales, Revenue and Gross Margin (2015-2020) 12.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Products Offered 12.4.5 Pfizer Recent Development 12.5 Ferring 12.5.1 Ferring Corporation Information 12.5.2 Ferring Description and Business Overview 12.5.3 Ferring Sales, Revenue and Gross Margin (2015-2020) 12.5.4 Ferring Overactive Bladder (OAB) Therapeutics Products Offered 12.5.5 Ferring Recent Development 12.6 GlaxoSmithKline 12.6.1 GlaxoSmithKline Corporation Information 12.6.2 GlaxoSmithKline Description and Business Overview 12.6.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020) 12.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Products Offered 12.6.5 GlaxoSmithKline Recent Development 12.7 Ion Channel Innovations 12.7.1 Ion Channel Innovations Corporation Information 12.7.2 Ion Channel Innovations Description and Business Overview 12.7.3 Ion Channel Innovations Sales, Revenue and Gross Margin (2015-2020) 12.7.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Products Offered 12.7.5 Ion Channel Innovations Recent Development 12.8 Kwang Dong Pharmaceutical 12.8.1 Kwang Dong Pharmaceutical Corporation Information 12.8.2 Kwang Dong Pharmaceutical Description and Business Overview 12.8.3 Kwang Dong Pharmaceutical Sales, Revenue and Gross Margin (2015-2020) 12.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered 12.8.5 Kwang Dong Pharmaceutical Recent Development 12.9 Lanzhou Institute of Biological Products 12.9.1 Lanzhou Institute of Biological Products Corporation Information 12.9.2 Lanzhou Institute of Biological Products Description and Business Overview 12.9.3 Lanzhou Institute of Biological Products Sales, Revenue and Gross Margin (2015-2020) 12.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Products Offered 12.9.5 Lanzhou Institute of Biological Products Recent Development 12.10 Merck 12.10.1 Merck Corporation Information 12.10.2 Merck Description and Business Overview 12.10.3 Merck Sales, Revenue and Gross Margin (2015-2020) 12.10.4 Merck Overactive Bladder (OAB) Therapeutics Products Offered 12.10.5 Merck Recent Development 12.11 Allergan 12.11.1 Allergan Corporation Information 12.11.2 Allergan Description and Business Overview 12.11.3 Allergan Sales, Revenue and Gross Margin (2015-2020) 12.11.4 Allergan Overactive Bladder (OAB) Therapeutics Products Offered 12.11.5 Allergan Recent Development 12.12 Sanofi 12.12.1 Sanofi Corporation Information 12.12.2 Sanofi Description and Business Overview 12.12.3 Sanofi Sales, Revenue and Gross Margin (2015-2020) 12.12.4 Sanofi Products Offered 12.12.5 Sanofi Recent Development 12.13 Tengion 12.13.1 Tengion Corporation Information 12.13.2 Tengion Description and Business Overview 12.13.3 Tengion Sales, Revenue and Gross Margin (2015-2020) 12.13.4 Tengion Products Offered 12.13.5 Tengion Recent Development 12.14 Teva Pharmaceutical Industries 12.14.1 Teva Pharmaceutical Industries Corporation Information 12.14.2 Teva Pharmaceutical Industries Description and Business Overview 12.14.3 Teva Pharmaceutical Industries Sales, Revenue and Gross Margin (2015-2020) 12.14.4 Teva Pharmaceutical Industries Products Offered 12.14.5 Teva Pharmaceutical Industries Recent Development 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Market Opportunities and Drivers 13.2 Market Challenges 13.3 Market Risks/Restraints 13.4 Porter’s Five Forces Analysis 13.5 Primary Interviews with Key Overactive Bladder (OAB) Therapeutics Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Overactive Bladder (OAB) Therapeutics Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

List of Tables Table 1. Overactive Bladder (OAB) Therapeutics Market Segments Table 2. Ranking of Global Top Overactive Bladder (OAB) Therapeutics Manufacturers by Revenue (US$ Million) in 2019 Table 3. Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Type 2020-2026 (MT) & (US$ Million) Table 4. Major Manufacturers of Anticholinergic Agents Table 5. Major Manufacturers of Beta-3 Adrenoreceptor Agonists Table 6. Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Application 2020-2026 (MT) Table 7. Global Overactive Bladder (OAB) Therapeutics Market Size by Region (MT) & (US$ Million): 2020 VS 2026 Table 8. Global Overactive Bladder (OAB) Therapeutics Sales by Regions 2015-2020 (MT) Table 9. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Regions (2015-2020) Table 10. Global Overactive Bladder (OAB) Therapeutics Revenue by Regions 2015-2020 (US$ Million) Table 11. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Region (2021-2026) (MT) Table 12. Global Overactive Bladder (OAB) Therapeutics Sales by Manufacturers (2015-2020) (MT) Table 13. Global Overactive Bladder (OAB) Therapeutics Sales Share by Manufacturers (2015-2020) Table 14. Global Overactive Bladder (OAB) Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020) Table 15. Global Overactive Bladder (OAB) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overactive Bladder (OAB) Therapeutics as of 2019) Table 16. Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers (2015-2020) (US$ Million) Table 17. Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2015-2020) Table 18. Key Manufacturers Overactive Bladder (OAB) Therapeutics Price (2015-2020) (USD/Kg) Table 19. Overactive Bladder (OAB) Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters Table 20. Manufacturers Overactive Bladder (OAB) Therapeutics Product Type Table 21. Date of International Manufacturers Enter into Overactive Bladder (OAB) Therapeutics Market Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans Table 23. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2015-2020) (MT) Table 24. Global Overactive Bladder (OAB) Therapeutics Sales Share by Type (2015-2020) Table 25. Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2015-2020) (US$ Million) Table 26. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2015-2020) Table 27. Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) by Type 2015-2020 (USD/Kg) Table 28. Global Overactive Bladder (OAB) Therapeutics Sales Share by Type (2021-2026) Table 29. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2015-2020) (MT) Table 30. Global Overactive Bladder (OAB) Therapeutics Sales Share by Application (2015-2020) Table 31. Global Overactive Bladder (OAB) Therapeutics Sales Share by Application (2021-2026) Table 32. Global Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Application (2021-2026) Table 33. Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2015-2020) (US$ Million) Table 34. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share Forecast by Application (2021-2026) Table 35. Japan Overactive Bladder (OAB) Therapeutics Sales (MT) of Key Companies (2015-2020) Table 36. Japan Overactive Bladder (OAB) Therapeutics Sales Share by Company (2015-2020) Table 37. Japan Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Company (2015-2020) Table 38. Japan Overactive Bladder (OAB) Therapeutics Sales (MT) by Type (2015-2020) Table 39. Japan Overactive Bladder (OAB) Therapeutics Sales Share by Type (2015-2020) Table 40. Japan Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) Market Share by Type (2015-2020) Table 41. Japan Overactive Bladder (OAB) Therapeutics Price (MT) by Type (2015-2020) Table 42. Japan Overactive Bladder (OAB) Therapeutics Sales (MT) by Type (2021-2026) Table 43. Japan Overactive Bladder (OAB) Therapeutics Sales Share by Type (2021-2026) Table 44. Japan Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) Market Share by Type (2021-2026) Table 45. Japan Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2021-2026) Table 46. Japan Overactive Bladder (OAB) Therapeutics Price (MT) by Type (2021-2026) Table 47. Japan Overactive Bladder (OAB) Therapeutics Sales (MT) by Application (2015-2020) Table 48. Japan Overactive Bladder (OAB) Therapeutics Sales Share by Application (2015-2020) Table 49. Japan Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) Market Share by Application (2015-2020) Table 50. Japan Overactive Bladder (OAB) Therapeutics Sales (MT) by Application (2021-2026) Table 51. Japan Overactive Bladder (OAB) Therapeutics Sales Share by Application (2021-2026) Table 52. Japan Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) Market Share by Application (2021-2026) Table 53. Japan Overactive Bladder (OAB) Therapeutics Revenue Share by Application (2021-2026) Table 54. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2015-2020) (MT) Table 55. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) Table 56. North America Overactive Bladder (OAB) Therapeutics Revenue by Country (2015-2020) (US$ Million) Table 57. North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) Table 58. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2015-2020) (MT) Table 59. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) Table 60. Europe Overactive Bladder (OAB) Therapeutics Revenue by Country (2015-2020) (US$ Million) Table 61. Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) Table 62. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region (2015-2020) (MT) Table 63. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2015-2020) Table 64. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region (2015-2020) (US$ Million) Table 65. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2015-2020) Table 66. Latin America Overactive Bladder (OAB) Therapeutics Sales by Country (2015-2020) (MT) Table 67. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) Table 68. Latin Americaa Overactive Bladder (OAB) Therapeutics Revenue by Country (2015-2020) (US$ Million) Table 69. Latin America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) Table 70. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2015-2020) (MT) Table 71. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) Table 72. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country (2015-2020) (US$ Million) Table 73. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) Table 74. Allergan Corporation Information Table 75. Allergan Description and Business Overview Table 76. Allergan Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 77. Allergan Overactive Bladder (OAB) Therapeutics Product Table 78. Allergan Recent Development Table 79. Astellas Pharma Corporation Information Table 80. Astellas Pharma Description and Business Overview Table 81. Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 82. Astellas Pharma Product Table 83. Astellas Pharma Recent Development Table 84. Hisamitsu Pharmaceutical Corporation Information Table 85. Hisamitsu Pharmaceutical Description and Business Overview Table 86. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 87. Hisamitsu Pharmaceutical Product Table 88. Hisamitsu Pharmaceutical Recent Development Table 89. Pfizer Corporation Information Table 90. Pfizer Description and Business Overview Table 91. Pfizer Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 92. Pfizer Product Table 93. Pfizer Recent Development Table 94. Ferring Corporation Information Table 95. Ferring Description and Business Overview Table 96. Ferring Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 97. Ferring Product Table 98. Ferring Recent Development Table 99. GlaxoSmithKline Corporation Information Table 100. GlaxoSmithKline Description and Business Overview Table 101. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 102. GlaxoSmithKline Product Table 103. GlaxoSmithKline Recent Development Table 104. Ion Channel Innovations Corporation Information Table 105. Ion Channel Innovations Description and Business Overview Table 106. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 107. Ion Channel Innovations Product Table 108. Ion Channel Innovations Recent Development Table 109. Kwang Dong Pharmaceutical Corporation Information Table 110. Kwang Dong Pharmaceutical Description and Business Overview Table 111. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 112. Kwang Dong Pharmaceutical Product Table 113. Kwang Dong Pharmaceutical Recent Development Table 114. Lanzhou Institute of Biological Products Corporation Information Table 115. Lanzhou Institute of Biological Products Description and Business Overview Table 116. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 117. Lanzhou Institute of Biological Products Product Table 118. Lanzhou Institute of Biological Products Recent Development Table 119. Merck Corporation Information Table 120. Merck Description and Business Overview Table 121. Merck Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 122. Merck Product Table 123. Merck Recent Development Table 124. ONO Pharmaceutical Corporation Information Table 125. ONO Pharmaceutical Description and Business Overview Table 126. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 127. ONO Pharmaceutical Product Table 128. ONO Pharmaceutical Recent Development Table 129. Sanofi Corporation Information Table 130. Sanofi Description and Business Overview Table 131. Sanofi Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 132. Sanofi Product Table 133. Sanofi Recent Development Table 134. Tengion Corporation Information Table 135. Tengion Description and Business Overview Table 136. Tengion Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 137. Tengion Product Table 138. Tengion Recent Development Table 139. Teva Pharmaceutical Industries Corporation Information Table 140. Teva Pharmaceutical Industries Description and Business Overview Table 141. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 142. Teva Pharmaceutical Industries Product Table 143. Teva Pharmaceutical Industries Recent Development Table 144. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 145. Key Challenges Table 146. Market Risks Table 147. Main Points Interviewed from Key Overactive Bladder (OAB) Therapeutics Players Table 148. Overactive Bladder (OAB) Therapeutics Customers List Table 149. Overactive Bladder (OAB) Therapeutics Distributors List Table 150. Research Programs/Design for This Report Table 151. Key Data Information from Secondary Sources Table 152. Key Data Information from Primary Sources List of Figures Figure 1. Overactive Bladder (OAB) Therapeutics Product Picture Figure 2. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type in 2020 & 2026 Figure 3. Anticholinergic Agents Product Picture Figure 4. Beta-3 Adrenoreceptor Agonists Product Picture Figure 5. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application in 2020 & 2026 Figure 6. Hosptial Figure 7. Clinci Figure 8. Other Figure 9. Overactive Bladder (OAB) Therapeutics Report Years Considered Figure 10. Global Overactive Bladder (OAB) Therapeutics Market Size 2015-2026 (US$ Million) Figure 11. Global Overactive Bladder (OAB) Therapeutics Sales 2015-2026 (MT) Figure 12. Global Overactive Bladder (OAB) Therapeutics Market Size Market Share by Region: 2020 Versus 2026 Figure 13. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2015-2020) Figure 14. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region in 2019 Figure 15. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2015-2020) Figure 16. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region in 2019 Figure 17. Global Overactive Bladder (OAB) Therapeutics Sales Share by Manufacturer in 2019 Figure 18. The Top 10 and 5 Players Market Share by Overactive Bladder (OAB) Therapeutics Revenue in 2019 Figure 19. Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 20. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2015-2020) Figure 21. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type in 2019 Figure 22. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2015-2020) Figure 23. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type in 2019 Figure 24. Global Overactive Bladder (OAB) Therapeutics Market Share by Price Range (2015-2020) Figure 25. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2015-2020) Figure 26. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application in 2019 Figure 27. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2015-2020) Figure 28. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application in 2019 Figure 29. Japan Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2015-2026 (MT) Figure 30. Japan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2015-2026 (US$ Million) Figure 31. Japan Overactive Bladder (OAB) Therapeutics Market Share in Global Market 2015-2026 Figure 32. Japan 5 and 10 Largest Overactive Bladder (OAB) Therapeutics Players Market Share by Revenue in Overactive Bladder (OAB) Therapeutics in 2019 Figure 33. Japan Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2015-2020) Figure 34. Japan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate by Type in 2015 & 2019 Figure 35. Japan Overactive Bladder (OAB) Therapeutics Revenue Share by Application (2015-2020) Figure 36. Japan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate by Application in 2015 & 2019 Figure 37. North America Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2015-2020 (MT) Figure 38. North America Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million) Figure 39. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country in 2019 Figure 40. North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country in 2019 Figure 41. U.S. Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 42. U.S. Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 43. Canada Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 44. Canada Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 45. Europe Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2015-2020 (MT) Figure 46. Europe Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million) Figure 47. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country in 2019 Figure 48. Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country in 2019 Figure 49. Germany Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 50. Germany Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 51. France Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 52. France Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 53. U.K. Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 54. U.K. Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 55. Italy Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 56. Italy Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 57. Russia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 58. Russia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 59. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2015-2020 (MT) Figure 60. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million) Figure 61. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Region in 2019 Figure 62. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region in 2019 Figure 63. China Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 64. China Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 65. Japan Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 66. Japan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 67. South Korea Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 68. South Korea Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 69. India Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 70. India Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 71. Australia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 72. Australia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 73. Taiwan Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 74. Taiwan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 75. Indonesia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 76. Indonesia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 77. Thailand Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 78. Thailand Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 79. Malaysia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 80. Malaysia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 81. Philippines Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 82. Philippines Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 83. Vietnam Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 84. Vietnam Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 85. Latin America Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2015-2020 (MT) Figure 86. Latin America Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million) Figure 87. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country in 2019 Figure 88. Latin America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country in 2019 Figure 89. Mexico Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 90. Mexico Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 91. Brazil Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 92. Brazil Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 93. Argentina Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 94. Argentina Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 95. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2015-2020 (MT) Figure 96. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million) Figure 97. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country in 2019 Figure 98. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country in 2019 Figure 99. Turkey Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 100. Turkey Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 101. Saudi Arabia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 102. Saudi Arabia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 103. U.A.E Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT) Figure 104. U.A.E Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million) Figure 105. Porter's Five Forces Analysis Figure 106. Overactive Bladder (OAB) Therapeutics Value Chain Figure 107. Channels of Distribution Figure 108. Distributors Profiles Figure 109. Bottom-up and Top-down Approaches for This Report Figure 110. Data Triangulation Figure 111. Key Executives Interviewed

Allergan Astellas Pharma Hisamitsu Pharmaceutical Pfizer Ferring GlaxoSmithKline Ion Channel Innovations Kwang Dong Pharmaceutical Lanzhou Institute of Biological Products Merck ONO Pharmaceutical Sanofi Tengion Teva Pharmaceutical Industries